August 26, 2021 – Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck that will facilitate the development of real-world research excellence and innovation.
This agreement enables the two companies to harness the power of real-world evidence towards the common goal of improving patient outcomes and the quality of cancer care.
As part of the agreement, Merck and Ontada can collaborate on real-world data studies to explore new scientific evidence, advanced methods development, and assessment of efficiency in cancer care.
Ontada combines real-world data and research capabilities, targeted channels to connect life sciences and providers for education and engagement, and a leading suite of technologies for oncology clinicians – including the iKnowMed electronic health record system and Clear Value Plus regimen support tool – with the reach of The US Oncology Network, supported by McKesson.
Susan Shiff, PhD, president of Ontada, shared, “Building on McKesson’s long history in community oncology, Ontada is uniquely positioned to advance cancer care by enabling collaboration between life sciences companies and oncology providers. With data insights from greater than two million records available for research and more than 2,000 oncology providers, Ontada helps life sciences companies like Merck leverage real-world data and evidence-based insights at the point of care to accelerate innovation and improve cancer therapy.”